-
A Survey Of Celgene's M&A Strategy
Friday, January 19, 2018 - 10:41am | 1550M&A activity has begun in the New Year, with the pharma sector leading from the front. Earlier this week, the Wall Street Journal reported Celgene Corporation (NASDAQ: CELG) is pursuing Juno Therapeutics Inc (NASDAQ: JUNO). The report triggered a massive 52-percent upward move in shares of...
-
A Dilutive Offering In The Offing? Oppenheimer Downgrades Synergy Pharma
Friday, January 5, 2018 - 3:41pm | 452Synergy Pharmaceuticals Inc (NASDAQ: SGYP) announced an offering of 21 million shares of its common stock at $2.58 per share in November, and at least one Wall Street analyst said another dilutive offering is imminent. The Analyst Oppenheimer's Derek Archila downgraded Synergy...
-
Argus Shares Eli Lilly's Optimism, Upgrades To Buy
Friday, January 5, 2018 - 2:54pm | 408If an 8-percent quarterly dividend increase is any indication, Eli Lilly and Co (NYSE: LLY) is confident of its growth potential. Its optimism echoes with one Wall Street analyst. The Rating Argus analyst David Toung upgraded Eli Lilly from Hold to Buy with a $115 price target. The Thesis...
-
11 Biotech Stocks Moving From ASH 2017
Monday, December 11, 2017 - 5:24pm | 1170The American Society of Hematology's 59th annual meeting continues through Tuesday in Atlanta. Although stocks reacted to the presentation of abstracts in early November, the full presentation elicited incremental reaction, with the direction and magnitude of the moves dependent on the market...
-
What If Trump Keeps Badmouthing Drug Pricing?
Wednesday, December 7, 2016 - 2:38pm | 400Pharmaceutical companies breathed a sigh of relief when Donald Trump prevailed on Election Day. His opponent, Hillary Clinton, had made prescription drug pricing a centerpiece of her campaign. However, according to Bernstein analyst Tim Anderson, pharma stocks may not be off the hook when Trump...
-
JPMorgan's Take On Big Pharma's New ASCO Abstracts
Thursday, May 19, 2016 - 11:07am | 322Abstracts for the ASCO 2016 meeting were released on Wednesday evening. With the event only a couple of weeks away, JPMorgan analyst Chris Schott took a look at what investors can expect from the ASCO presentations of four big-name pharma companies. For Eli Lilly and Co (NYSE: LLY), ASCO will be...
-
Not All Of Clinton's Policies Are Bad For Pharmaceuticals
Wednesday, December 23, 2015 - 3:13pm | 433Earlier this year pharmaceutical firms began to worry about the upcoming 2016 elections after Presidential hopeful Hillary Clinton announced plans to regulate drug pricing further to ensure that healthcare costs don't skyrocket. While that proposal was well received by consumers, drug...
-
Eli Lilly Discontinues Evacetrapib; Investors Move Bets To Alternatives
Monday, October 12, 2015 - 9:56am | 342Eli Lilly and Co (NYSE: LLY) shares are plunging nearly 8.0 percent in early trading on Monday after the company announced that it is discontinuing development of cardiovascular disease treatment drug evacetrapib because of disappointing efficacy. Here’s a look at what shareholders can...
-
5-Star Biotech Stock Watch: Synta Pharmaceuticals
Wednesday, June 18, 2014 - 3:26pm | 429It seems as if mergers and acquisitions in the healthcare sector has become commonplace, with a lot of biotech companies being main targets. Not a week goes by without multiple discussions about the battle between Valeant Pharmaceuticals (NYSE: VRX) and Allergan(NYSE: AGN). Last week brought...
-
Takeover Whispers Add To Achillion Pharmaceuticals' Momentum
Wednesday, June 11, 2014 - 4:22pm | 757In this momentum-driven market, sector or company-specific news can have a significant impact on the price of individual issues. Wall Street analysts weighing in on the issue may also add to the momentum already in place. An example is Achillion Pharmaceuticals (NASDAQ: ACHN), where all of...
-
Which Sector Produced 8 Of The 10 Top Percentage Gainers In 2014?
Tuesday, February 11, 2014 - 4:29pm | 801With January effect not producing the most promising results for the overall market, one sector that did was the pharma sector. So far this year, this sector has produced eight of the top ten percentage gainers. The sector, primarily known for producing big winners and big losers, has...
-
Investor Ideas' Biotech and Pharma News: Unity Management Group
Wednesday, December 14, 2011 - 4:43pm | 468East Hanover, N.J. - December 14, 2011 (Investorideas.com Newswire) - Unity Management Group, Inc. (OTCBB: UYMG) and its subsidiary, Metropolitan Computing Corporation (MCC) are pleased to announce that it has sold its initial PZ Uno Tablet press to a major pharmaceutical company for $500,000. Due...
-
Investor Ideas' Biotech Stock Trading Alert: Aethlon Medical Trades Up over 9% on News of HIV-AIDS Research Discovery
Tuesday, December 13, 2011 - 3:41pm | 596Point Roberts, WA - December 13, 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for Aethlon Medical, Inc. (OTCBB: AEMD) following news of its HIV-AIDS research discovery. The stock is trading up...
-
Investor Ideas' Biotech Stock Investor News Alert; Aethlon Medical Announces HIV-AIDS Research Discovery
Tuesday, December 13, 2011 - 2:20pm | 1158San Diego, December 13, 2011 - (Investorideas.com Newswire) Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that researchers have discovered that the Aethlon Hemopurifier® is able to capture...
-
Investor Ideas' Biotech/ Pharma Stocks To Watch: Friday's Gainers
Monday, December 12, 2011 - 12:46pm | 522Point Roberts, WA - December 12, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an investor alert for some of the top trading stocks in the sector for Friday, December 09, 2011. Poniard Pharmaceuticals, Inc. (NASDAQ...